Achieve Life Sciences, Inc. announced a director or officer change
SEC 8-KRead source ↗
Achieve Life Sciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
- Funds82 adding, 31 cuttingOf 22 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 18.4% while net income fell 126.2%: a 108pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Achieve Life Sciences, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
- Share dilution. Diluted shares rose 82.2% in a year.
- Volatile shares. Over the past year the shares showed annualised volatility of 80% and a beta of 1.9 against the S&P 500.
- Heavily shorted. 17.4% of the shares available to trade are sold short (12.2 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$0.80 against an average estimate of -$0.16: missed by 400.0%
- Share reaction
- +0.3% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
- Next report
- November 5, 2026; average EPS estimate -$0.19
Price chart
- 1 day-3.2%
- 1 week+1.1%
- 1 month-8.7%
- This year+33.0%
- 1 year+29.1%
- 5 years-25.3%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-1.81
Growth
- Share count change
- +82.2%
Earnings
- Last results
- August 11, 2026
- Next results (est.)
- November 5, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Leadership
- Announcement
Achieve Life Sciences, Inc. disclosed a material event
SEC 8-KRead source ↗ - Results
Achieve Life Sciences, Inc. reported results
SEC 8-KRead source ↗ - Shareholder vote
Achieve Life Sciences, Inc. amended its charter or bylaws; reported shareholder vote results
SEC 8-KRead source ↗
No model value for Achieve Life Sciences, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Achieve Life Sciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10%: the 10-year Treasury yield (4.9%) plus a beta of 1.13 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$1.1 ~$1.2–$4.3 | Left out: out of range vs price (0.17x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Achieve Life Sciences, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 5, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.19 (range −$0.36 to −$0.11) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.38 | −10% | — | 0% |
| Next | −$0.65 | +53% | $38m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +101.6% on 90 days ago. In the last 30 days, 0 analysts raised Achieve Life Sciences, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.68 | −$0.49 |
| 60 days ago | −$1.37 | −$0.64 |
| 30 days ago | −$1.37 | −$0.64 |
| 7 days ago | −$1.38 | −$0.65 |
| Now | −$1.38 | −$0.65 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.16 | −$0.80 | −400.0% |
| Mar 2026 | −$0.30 | −$0.19 | +36.4% |
| Dec 2025 | −$0.28 | −$0.28 | −1.2% |
| Sept 2025 | −$0.26 | −$0.28 | −7.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 17.4% of tradable shares
- Days to cover
- 12.17 at average volume
- Short interest, 1 month
- +11% to October 15, 2026
- Held by institutions
- 82% of shares
- Held by insiders
- 0.9% of shares
- Employees
- 28 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| ACHV | −4% | −69% | +68% | −15% | +41% | +33% |
| Industry peers (median) | −36% | −56% | −18% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| ACHV | 50% | 33% | 42% | 42% | 50% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| ACHV | −57% | −76% | −68% | −36% | −51% | −55% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from November 27, 2015 to April 8, 2025. Getting back needed a 303233% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $2.65 – $8.53
- From 52-week high
- −22.5%
- vs 50-day average
- −11.0%
- vs 200-day average
- +17.1%
- Volatility (1 year)
- 81%
- Beta vs S&P 500
- 1.91
Share price after results
- Next day
- 4 up, 8 down typical move ±6.5%
- After a week
- 4 up, 8 down typical move ±11.5%
- After a month
- 8 up, 4 down typical move ±10.1%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 11, 2026 | +0.3% | −0.1% | +12.7% | +9.1% |
| May 12, 2026 | +6.6% | +0.4% | −20.4% | −1.3% |
| March 24, 2026 | −30.4% | +0.2% | −27.4% | +2.5% |
| November 6, 2025 | −6.9% | −1.0% | −7.1% | −4.9% |
| August 7, 2025 | −5.3% | +0.7% | −3.4% | +11.0% |
| May 13, 2025 | 0.0% | +0.8% | +31.5% | +33.9% |
| March 11, 2025 | −13.4% | −0.3% | −9.2% | −30.1% |
| November 7, 2024 | −9.6% | +1.2% | −14.3% | −10.9% |
| August 13, 2024 | +0.9% | +2.0% | +1.6% | +0.2% |
| May 9, 2024 | −2.1% | +0.7% | +7.6% | +13.6% |
| March 28, 2024 | +1.3% | −0.2% | −1.3% | +1.1% |
| February 29, 2024 | −0.9% | +1.3% | −1.8% | +2.7% |
Fundamentals
Financial statements
| Fiscal year | 2018 Dec 2018 | 2019 Dec 2019 |
|---|---|---|
| Income | ||
| Revenue | 0 | 0 |
| Net income | −13 | −16 |
| Diluted EPS | −$72.29 | −$39.76 |
| Cash flow | ||
| Cash from operations | −11 | −15 |
| Capital spending | 0 | 0 |
| Free cash flow | −11 | −15 |
| Stock-based pay | 1 | 1 |
| Free cash flow after stock pay | −12 | −16 |
| Balance sheet | ||
| Cash | 10 | 17 |
| Total debt | 0 | 0 |
| Net debt (negative = net cash) | −10 | −17 |
| Diluted shares | — | — |
Dividends, buybacks and capital spending
- Diluted share count
- +82.2%
- year over year
Who owns it
Funds buying and selling- Reported value
- $539M
- Institutions reporting
- 111
- Shares held vs prior quarter
- ▲ 284.0%
- Positions opened / closed
- 48 / 17
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $49.7M | 7.6M | 9.2% | New |
| Tpg Gp A, LLC | $44.9M | 6.9M | 8.3% | New |
| Venbio Partners LLC | $38.6M | 5.9M | 7.2% | New |
| Logos Global Management LP | $35.4M | 5.4M | 6.6% | New |
| Blackrock, Inc. | $34.4M | 5.3M | 6.4% | ▲ 1099.9% |
| Franklin Resources Inc | $32.3M | 5.0M | 6.0% | ▲ 13.4% |
| Paradigm Biocapital Advisors LP | $32.3M | 5.0M | 6.0% | New |
| Vanguard Capital Management LLC | $27M | 4.1M | 5.0% | ▲ 87.8% |
| Propel Bio Management, LLC | $26.3M | 4.0M | 4.9% | ▲ 6.5% |
| Marshall Wace, LLP | $24.6M | 3.8M | 4.6% | ▲ 269.9% |
| State Street Corp | $19.2M | 2.9M | 3.6% | ▲ 1057.6% |
| Jupiter Topco LLC | $18M | 2.8M | 3.3% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Achieve Life Sciences, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $175,115 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $175,115 net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Stewart Richard Alistair Director | August 19, 2026 | Sell | 20,626 | $8.49 | $175,115 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
- August 11, 2026
- May 12, 2026
- March 24, 2026
- November 6, 2025
- August 7, 2025
- May 13, 2025
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- S-3 S-3
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Achieve Life Sciences, Inc. in brief
- What does Achieve Life Sciences, Inc. do?
- Achieve Life Sciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Achieve Life Sciences, Inc.'s stock ticker?
- Achieve Life Sciences, Inc. trades under the ticker ACHV on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Achieve Life Sciences, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Frazier Life Sciences Management, L.P., Tpg Gp A, LLC and Venbio Partners LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- What is Achieve Life Sciences, Inc.'s market cap?
- On December 31, 2019, Achieve Life Sciences, Inc.'s market capitalisation was about $4.4M and net debt of -$16.7M. Market figures come from third-party market data and may be delayed.
- Are insiders buying or selling Achieve Life Sciences, Inc. stock?
- Over the last 12 months, Achieve Life Sciences, Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
- When is Achieve Life Sciences, Inc.'s next earnings date?
- Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Achieve Life Sciences, Inc. announces its own schedule.
Follow research on Achieve Life Sciences, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.